{"url_path":"/sec/humaw/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1818382/0001193125-26-221755-index.html","accession_number":"0001193125-26-221755","cik":"0001818382","ticker":"HUMA","issuer_name":"Humacyte, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818382/0001193125-26-221755-index.html","primary_entity_key":"0001818382","primary_entity_name":"Humacyte, Inc."},"word_count":386,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nThe following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n10.1\n\n \n\n[Third Amendment to Distribution Agreement, dated April 21, 2026, by and between Humacyte Global, Inc. and Fresenius Medical Care Holdings, Inc. (incorporated by reference to Exhibit 10.1 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on April 24, 2026).](https://www.sec.gov/Archives/edgar/data/1818382/000110465926048164/tm2612631d1_ex10-1.htm)\n\n \n\n \n\n \n\n31.1*\n\n \n\nCertification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n \n\n31.2*\n\n \n\nCertification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n \n\n32.1**\n\n \n\nCertification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n \n\n32.2**\n\n \n\nCertification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n \n\n101*\n\n \n\nThe following materials from Humacyte, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (unaudited), (iii) Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited), (v) Notes to Condensed Consolidated Financial Statements (unaudited), and (vi) Cover Page.\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n* Filed herewith.\n\n** This exhibit is being furnished rather than filed, and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.\n\n62\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 13th day of May, 2026.\n\n \n\n \n\nHUMACYTE, INC.\n\n \n\n \n\nDate: May 13, 2026\n\nBy:\n\n /s/ Laura E. Niklason, M.D., Ph.D.\n\n \n\n \n\nName:\n\n Laura E. Niklason, M.D., Ph.D.\n\n \n\n \n\nTitle:\n\nPresident and Chief Executive Officer\n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n /s/ Dale A. Sander\n\n \n\n \n\nName:\n\n Dale A. Sander\n\n \n\n \n\nTitle:\n\nChief Financial Officer, Chief Corporate\n\n \n\n \n\n \n\nDevelopment Officer and Treasurer\n\n \n\n63"}